Pharmacologic Prevention of Noise and Drug-induced Hearing Loss: Current State of Development of Antioxidant Otoprotection Within the next decade audiologists will be working with patients and physicians in selecting and monitoring pharmacologic otoprotective agents against drug and noise induced hearing loss either for research or clinic applications or both. Currently, several of these agents are in clinical trials, although none yet have Food and Drug ... Article
Article  |   April 01, 2011
Pharmacologic Prevention of Noise and Drug-induced Hearing Loss: Current State of Development of Antioxidant Otoprotection
Author Affiliations & Notes
  • Kathleen Campbell
    Southern Illinois University School of Medicine, Springfield, IL
    Director of Audiology Research
Article Information
Hearing Disorders / Articles
Article   |   April 01, 2011
Pharmacologic Prevention of Noise and Drug-induced Hearing Loss: Current State of Development of Antioxidant Otoprotection
SIG 6 Perspectives on Hearing and Hearing Disorders: Research and Diagnostics, April 2011, Vol. 15, 15-24. doi:10.1044/hhd15.1.15
SIG 6 Perspectives on Hearing and Hearing Disorders: Research and Diagnostics, April 2011, Vol. 15, 15-24. doi:10.1044/hhd15.1.15
Abstract

Within the next decade audiologists will be working with patients and physicians in selecting and monitoring pharmacologic otoprotective agents against drug and noise induced hearing loss either for research or clinic applications or both. Currently, several of these agents are in clinical trials, although none yet have Food and Drug Administration approval for clinical use.

Become a SIG Affiliate
Pay Per View
Entire SIG 6 Perspectives on Hearing and Hearing Disorders: Research and Diagnostics content & archive
24-hour access
This Issue
24-hour access
This Article
24-hour access
We've Changed Our Publication Model...
The 19 individual SIG Perspectives publications have been relaunched as the new, all-in-one Perspectives of the ASHA Special Interest Groups.